ITAT rules on pricing method of generic active pharmaceutical ingredients (API)

Rohan Phatarphekar and Manish Bafna, of KPMG, dissect the Mumbai ITAT ruling in the case of Serdia Pharmaceuticals and explain why APIs can constitute a comparable uncontrolled price (CUP) for the import of drugs when the patent has expired.

Locked content

The article you are trying to view is only available to subscribers and current trialists